AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Oruka Therapeutics, Inc. Director's Dealing 2017

Mar 27, 2017

32280_dirs_2017-03-27_5fd8815c-a38c-485f-b34f-1f284679f1ef.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARCA biopharma, Inc. (ABIO)
CIK: 0000907654
Period of Report: 2017-03-24

Reporting Person: CONWAY ROBERT E (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-03-24	Common Stock	P	25000	$2.59	Acquired	25000	Direct

Footnotes

F1: The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from
$2.52 to $2.75. Upon request of the SEC staff, ARCA biopharma, Inc. (the "Company") or a security holder of the Company, the reporting person
will provide full information regarding the number of shares sold at each separate price